ANI Pharmaceuticals (ANIP) HR chief Krista Davis sells 3,814 shares under 10b5-1 plan

Rhea-AI Filing Summary

ANI Pharmaceuticals senior vice president and chief human resources officer Krista Davis sold a total of 3,814 shares of Common Stock in open‑market transactions. She sold 2,084 shares at a weighted average price of $77.53 on February 19, 2026 and 1,730 shares at $77.99 on February 20, 2026. The sales were executed under a Rule 10b5‑1 trading plan adopted on September 18, 2025, and she held 49,263 shares directly after the most recent sale.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Davis Krista

(Last) (First) (Middle)

C/O ANI PHARMACEUTICALS, INC.

210 MAIN STREET WEST

(Street)

BAUDETTE MN 56623

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
ANI PHARMACEUTICALS INC [ ANIP ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	SVP, CHIEF HR OFFICER

3. Date of Earliest Transaction (Month/Day/Year)
02/19/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	02/19/2026		S(1)		2,084	D	$77.53	50,993	D
Common Stock	02/20/2026		S(1)		1,730	D	$77.99(2)	49,263	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 18, 2025.

2. The shares were sold in multiple trades at prices ranging from $77.45 to $78.58. The price reported above reflects the weighted average sales price.

Remarks:

	/s/ Krista Davis, by attorney-in-fact Meredith W. Cook	02/23/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did ANI Pharmaceuticals (ANIP) report for Krista Davis?

ANI Pharmaceuticals reported that SVP and chief human resources officer Krista Davis sold 3,814 shares of common stock in open‑market transactions, executed over two days at weighted average prices of $77.53 and $77.99, under a pre‑established Rule 10b5‑1 trading plan.

How many ANI Pharmaceuticals (ANIP) shares did Krista Davis sell and at what prices?

Krista Davis sold 2,084 ANI Pharmaceuticals common shares at a weighted average price of $77.53 and 1,730 shares at $77.99. Footnotes state these prices reflect weighted averages of multiple trades within ranges from $77.45 to $78.58.

Does Krista Davis still hold ANI Pharmaceuticals (ANIP) shares after the reported sales?

Yes. After the most recent open‑market sale on February 20, 2026, Krista Davis directly held 49,263 shares of ANI Pharmaceuticals common stock. This post‑transaction balance reflects her remaining ownership following the total sale of 3,814 shares disclosed in the Form 4.

Were Krista Davis’s ANI Pharmaceuticals (ANIP) stock sales under a Rule 10b5-1 plan?

The filing states the reported sales were effected under a Rule 10b5‑1 trading plan adopted by Krista Davis on September 18, 2025. Such plans allow insiders to pre‑schedule trades, providing structure around transactions while they may later possess material nonpublic information.

What type of transaction code is used in Krista Davis’s ANI Pharmaceuticals (ANIP) Form 4?

The Form 4 lists transaction code “S” for Krista Davis’s trades, described as sales in open‑market or private transactions. Both entries involve non‑derivative common stock, reflecting straightforward share disposals rather than option exercises, gifts, or tax‑withholding events.

Is Krista Davis’s ownership in ANI Pharmaceuticals (ANIP) direct or indirect?

The transactions in the Form 4 are marked as “D” for direct ownership, with no additional entity noted in the nature of ownership field. This indicates the reported ANI Pharmaceuticals common stock is held directly by Krista Davis rather than through a trust, partnership, or other vehicle.